Solid tumor cell therapy Market Outlook 2026–2038: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines solid tumor cell therapy, the use of tumor infiltrating lymphocytes, engineered T cell receptors and other engineered cells to treat solid cancers that have not responded to antibodies and checkpoint inhibitors. It tests how fast approved products in melanoma extend to lung cancer, sarcoma and other tumours, and which participants capture value among developers, large biopharma firms, manufacturers and treatment centres.

Iovance Biotherapeutics reported record second quarter 2026 revenue of about USD 99 million, of which about USD 91 million came from its tumor infiltrating lymphocyte therapy Amtagvi (lifileucel) in the United States, and in September 2026 raised full year revenue guidance to USD 410–420 million. The conclusion is that a cell therapy for a solid tumor can be sold at scale to treatment centres, which was an open question when the product launched at a list price of about USD 515,000.

Clinical evidence is now reaching beyond melanoma. In October 2026 updated results from the IOV-LUN-202 trial showed an objective response rate of 24.6% in 69 patients with non-squamous non-small cell lung cancer after earlier treatment, and a supplemental application is planned in 2027. The conclusion is that lung cancer is the first large test of whether tumor infiltrating lymphocytes work outside melanoma, and a response in about one in four patients is enough to justify registration but not yet routine use.

Regulators and developers are building on this base. The FDA granted Fast Track designation to lifileucel in second line lung cancer in February 2026 and in soft tissue sarcomas in August 2026, Australia approved Amtagvi for advanced melanoma in June 2026, and Immatics reported a deep and durable remission in a child with metastatic nephroblastoma treated with a PRAME directed T cell receptor therapy in April 2026. The conclusion is that the field is moving from one approved product toward a set of targets and tumour types, with response rates, cost and treatment complexity as the limits.

The brief treats solid tumor cell therapy as an emerging category with a twelve year horizon to 2038. It identifies which cancers, regions and operators scale first and what each means for developers, large biopharma firms, manufacturers and treatment centres.

It is a focused 106-page decision brief for biopharma firms, suppliers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which cancers scale first and who captures value.

Tumor infiltrating lymphocyte therapy takes T cells from a patient tumour, expands them outside the body and returns them after lymphodepletion and interleukin-2. Lifileucel is the approved example.

T cell receptor engineered therapy equips T cells from the patient with a receptor that recognises a tumour protein presented inside cancer cells, such as PRAME, and can reach targets that antibodies cannot.

CAR-T and other engineered cells for solid tumors target surface proteins and face a harder environment than in blood cancer. Armored cells that carry added signals, such as an interleukin-12 tethered TIL product cleared for a first trial in June 2026, aim to improve this.

Uses are advanced melanoma today, with lung cancer, sarcoma and other solid tumours under study, each under cell and gene therapy regulation.

The limits are low response rates outside melanoma, tumour penetration, toxicity of lymphodepletion and interleukin-2, and the cost and complexity of making a product for each patient. The decade turns on whether response rates and durability reach a level that justifies the treatment burden.

The solid tumor cell therapy market, covering approved and late-stage tumor infiltrating lymphocyte, T cell receptor engineered and other cell therapies for solid cancers, related licensing and collaboration revenue, and related manufacturing and services, is valued at USD 0.3–0.5 billion in 2026 and is projected to reach USD 5.80–9.67 billion by 2038, at a CAGR of 28%.

The 2026 base rests on sales of the approved TIL therapy, licensing and collaboration income, and manufacturing services. Growth then follows approvals in lung cancer and sarcoma, T cell receptor products and international launches.

The forecast is sensitive to response and survival data, competition from antibodies and T cell engagers, manufacturing cost and reimbursement. Regionally, North America leads on sales and trials, Europe on academic research, and Asia-Pacific on early launches and fast following developers.

Scenarios.

The base case assumes lung cancer and sarcoma registrations around 2028 to 2029 and T cell receptor approvals in the early 2030s, giving the inflection in 2033. An accelerated case assumes strong survival data and lower manufacturing cost, bringing the inflection to 2031 and lifting the 2038 value to the top of the range. A delayed case assumes weak durability and competition from T cell engagers and antibody drug conjugates, holding growth at the bottom of the range.

Growth drivers

• Patients who progress after checkpoint inhibitors.
• First approvals in melanoma and sarcoma.
• Early data in lung cancer and sarcoma.
• Expansion of authorized treatment centres.

Enablers

• Venture funding and financing rounds.
• Biopharma licensing and partnerships.
• Public research funding.
• Commercial manufacturing and supply networks.

Restraints and barriers

• Low response rates outside melanoma.
• Competition from antibodies and T cell engagers.
• Tumor penetration limits.
• Cost and complexity of treatment.

The direction of solid tumor cell therapy is set by the need for options after checkpoint inhibitors, regulation, new targets and engineered cells, treatment centre adoption and partnering, and manufacturing cost.

The key participants in solid tumor cell therapy include Iovance Biotherapeutics, Inc., Immatics N.V., Instil Bio, Inc., Lyell Immunopharma, Inc., Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., Eli Lilly and Company, AstraZeneca PLC, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, BioNTech SE, Moderna, Inc., Lonza Group Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Miltenyi Biotec B.V. & Co. KG, Charles River Laboratories International, Inc., Sartorius AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, AbbVie Inc., The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Netherlands Cancer Institute, American Society of Clinical Oncology, European Society for Medical Oncology, Society for Immunotherapy of Cancer, American Society of Gene & Cell Therapy, Alliance for Regenerative Medicine, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, Therapeutic Goods Administration, Health Canada, International Council for Harmonisation, Foundation for the Accreditation of Cellular Therapy and United States Pharmacopeia.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as solid tumor cell therapy matures.

Iovance Biotherapeutics leads on approved product and sales, with Immatics, Instil Bio and Lyell Immunopharma developing T cell receptor, TIL and engineered cell programmes, while large biopharma and oncology firms, manufacturing and tools suppliers, cancer centres and societies, regulators, and standards bodies shape how fast these therapies reach patients. Competitive intensity is moderate in 2026 because one TIL product is on the market and most others are early, and it rises as lung cancer data arrive and large firms reposition.

Where value migrates.

In 2026 value sits with the developer of the approved TIL therapy and with the cell manufacturing and tools suppliers it relies on. By 2033 it moves toward companies with approved products in several cancers and survival data, because payers and treatment centres choose therapies with proven benefit after checkpoint inhibitors. By 2038 it settles in integrated cell therapy and manufacturing platforms and in suppliers with scaled processing. Margins hold for products with survival benefit and narrow for late followers.

The signals converge on a first commercial proof and an open question on breadth. An approved TIL therapy reached about USD 99 million of quarterly revenue in 2026, guidance was raised, and Fast Track designations followed in lung cancer and sarcoma. Each signal supports growth, and a response rate of 24.6% in lung cancer still has to be confirmed in a registrational setting.

Structural limits show where progress could slow: low response rates outside melanoma, tumour penetration, competition from T cell engagers and antibodies, and the cost and complexity of treatment. The brief therefore tracks four indicators: sales of approved products, registrational filings, T cell receptor trial data and new partnerships or acquisitions.

Melanoma, then lung cancer and sarcoma, then T cell receptor products for other tumours are the expected order of development.